Global Insulin API Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Insulin API Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.

In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.

In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.

According to our (Global Info Research) latest study, the global Insulin API market size was valued at US$ 1853 million in 2023 and is forecast to a readjusted size of USD 2248 million by 2030 with a CAGR of 2.8% during review period.

The major players in global Insulin API market include Novo Nordisk, Sanofi-Aventis, etc. The top 2 players occupy over 65% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Insulin Analogue is the main market, and occupies about 90% of the global market. Long-Acting is the main type, with a share over 40%.

This report is a detailed and comprehensive analysis for global Insulin API market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Insulin API market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Insulin API market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Insulin API market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Insulin API market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Insulin API

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Insulin API market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novo Nordisk, Sanofi-Aventis, Eli Lilly, Tonghua Dongbao, Ganlee, United Laboratory, Biocon, Amphastar, Wockhardt, Julphar Diabetes, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Insulin API market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Regular Human Insulin
Insulin Analogue

Market segment by Application
Fast-Acting
Premix
Long-Acting

Major players covered
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
Ganlee
United Laboratory
Biocon
Amphastar
Wockhardt
Julphar Diabetes
Torrent Pharma

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Insulin API product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Insulin API, with price, sales quantity, revenue, and global market share of Insulin API from 2019 to 2024.

Chapter 3, the Insulin API competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Insulin API breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Insulin API market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Insulin API.

Chapter 14 and 15, to describe Insulin API sales channel, distributors, customers, research findings and conclusion.